Nuclear factor erythroid 2-related factor 2

Banner Life Sciences Receives Favorable Appellate Court Decision in Biogen Patent Infringement Dispute

Retrieved on: 
Tuesday, April 21, 2020

We are pleased with the Federal Circuits decision, said Franck Rousseau, M.D., Chief Executive Officer of Banner.

Key Points: 
  • We are pleased with the Federal Circuits decision, said Franck Rousseau, M.D., Chief Executive Officer of Banner.
  • BAFIERTAM (monomethyl fumarate) is an oral 95 mg delayed-release capsule indicated for the treatment of patients with relapsing forms of multiple sclerosis.
  • While BAFIERTAM has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, the precise mechanism of action has not been fully elucidated.
  • Banner Life Sciences LLC, a privately held clinical-stage pharmaceutical company, combines a proven history of formulation expertise with proprietary technologies to create specialty pharmaceuticals that solve real unmet clinical needs.

Nuclear Factor Erythroid 2 Related Factor 2 - 2020 Pipeline Review, H1 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 6, 2020

The "Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 39 molecules.
  • The report, Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review H1 2020 outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics development with respective active and dormant or discontinued projects.

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline & Therapeutics Landscape, 2020

Retrieved on: 
Friday, April 3, 2020

DUBLIN, April 3, 2020 /PRNewswire/ -- The "Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 3, 2020 /PRNewswire/ -- The "Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 39 molecules.
  • The report, Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review H1 2020 outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics development with respective active and dormant or discontinued projects.

LifeVantage Opens for Business in New Zealand

Retrieved on: 
Tuesday, November 12, 2019

SALT LAKE CITY, Nov. 12, 2019 (GLOBE NEWSWIRE) -- As part of its continued global expansion, LifeVantage Corporation (Nasdaq:LFVN)has formally commenced business in New Zealand.

Key Points: 
  • SALT LAKE CITY, Nov. 12, 2019 (GLOBE NEWSWIRE) -- As part of its continued global expansion, LifeVantage Corporation (Nasdaq:LFVN)has formally commenced business in New Zealand.
  • New Zealand has demonstrated steady growth since opening as a customer market, said Courtland Pearson, LifeVantage Senior Vice President of Global Field Development, Asia Pacific.
  • New Zealand will initially offer Protandim Nrf1 Synergizer, Protandim Nrf2 Synergizer, ProBio probiotic supplement, TrueScience Skin Care System, and TrueScience Hair Care System.
  • With the addition of New Zealand, LifeVantage now serves 16 markets globally and four additional markets through its global customer and cross-border e-commerce programs.

Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators

Retrieved on: 
Thursday, October 10, 2019

As a result, Reata now possesses exclusive, worldwide rights to develop, manufacture and commercialize bardoxolone methyl (bardoxolone), omaveloxolone, and all other next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone which are licensed to Kyowa Kirin Co., Ltd.

Key Points: 
  • As a result, Reata now possesses exclusive, worldwide rights to develop, manufacture and commercialize bardoxolone methyl (bardoxolone), omaveloxolone, and all other next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone which are licensed to Kyowa Kirin Co., Ltd.
    As consideration for the rights reacquired by Reata, AbbVie will receive a total of $330 million in cash, primarily for rights to bardoxolone.
  • In addition, AbbVie will receive low single-digit, tiered royalties from worldwide sales of omaveloxolone and certain next-generation Nrf2 activators, and no royalties on bardoxolone.
  • Regaining these rights will increase Reatas strategic flexibility and control regarding the development and commercialization of our lead drug candidates, and our next-generation Nrf2 activators.
  • Reata has also entered into an amendment to its loan and security agreement with Oxford Finance LLC and Silicon Valley Bank.